CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...
Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
19 Apr 2021
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
16 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
16 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
9 Apr 2021
Cemiplimab plus ipilimumab for advanced NSCLC
Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
7 Apr 2021
IMpower133: Exploratory analysis of maintenance therapy in patients with exten...
Prof Martin Reck and Dr Antonio Passaro
1 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
1 Apr 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
29 Mar 2021
